Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors

Glycemic control and body weight loss, and hence amelioration of Hcy level by Vilda as add-on therapy to Met in Egyptian T2DM obese patients are subjected to genetic variation in one or more of the DPP-4, GLP1R and KATP genes involved in Vilda's modes of action. The GG genotype for the three genes is associated with better glycemic response; however, the AA genotype of GLP1R is associated with better weight loss response. Gender has no effect; however, lower initialbody weight results in better glycemic and weight loss response.